Gene, Cell and Tissue

Published by: Kowsar

Epigenetic BRCA2 Gene in Epithelial Ovarian Cancer

Fayazeh Sarjooghian 1 , Kahin Shahanipour 1 , * and Ahmad Shabanizadeh 2
Authors Information
1 Department of Biochemistry, Falavarjan Branch, Islamic Azad University, Isfahan,IR Iran
2 Department of Anatomy, Rafsanjan University Of Medical Sciences, Rafsanjan,IR Iran
Article information
  • Gene, Cell and Tissue: April 01, 2015, 2 (2); e28416
  • Published Online: April 1, 2015
  • Article Type: Research Article
  • Received: February 24, 2015
  • Revised: March 3, 2015
  • Accepted: March 11, 2015
  • DOI: 10.17795/gct-28416

To Cite: Sarjooghian F, Shahanipour K, Shabanizadeh A. Epigenetic BRCA2 Gene in Epithelial Ovarian Cancer, Gene Cell Tissue. 2015 ; 2(2):e28416. doi: 10.17795/gct-28416.

Abstract
Copyright © 2015, Zahedan University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer. Methods Mol Biol. 2009; 472: 413-37[DOI][PubMed]
  • 2. Robert LN, Rodrick RM. Genetic in medicine. 2001; : 125-50
  • 3. Asadollahi R, Hyde CA, Zhong XY. Epigenetics of ovarian cancer: from the lab to the clinic. Gynecol Oncol. 2010; 118(1): 81-7[DOI][PubMed]
  • 4. Swisher EM, Gonzalez RM, Taniguchi T, Garcia RL, Walsh T, Goff BA, et al. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer. 2009; 8: 48[DOI][PubMed]
  • 5. Berek J, Hacker N. Ovarian cancer in: Novak Gynecology . 1996; : 1155
  • 6. Disaia P, Creasman W. Epithelial ovarian cancer in: Gynecologic oncology. 1997; : 282-9
  • 7. Lucchetti MC. Ovarian tumours: general approach and balance between risk of unnecessary surgery and oncological risk. Paediatrics and Child Health. 2009; 19-7[DOI]
  • 8. Danforth . Obsterics and gynecology. 2008; : 554-63
  • 9. Kumar V. Robbins basic pathology. 2007; : 462-8
  • 10. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000; 19(1): 3-10[PubMed]
  • 11. Quinn JE, Carser JE, James CR, Kennedy RD, Harkin DP. BRCA1 and implications for response to chemotherapy in ovarian cancer. Gynecol Oncol. 2009; 113(1): 134-42[DOI][PubMed]
  • 12. Ghaemmaghami F, Modares Gilani M, Sadegi Fard NA. case-control study of risk factors for epithelial ovarian cancer. Med J. 2001; 4: 57-62
  • 13. King MC, Marks JH, Mandell JB, New York Breast Cancer Study G. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003; 302(5645): 643-6[DOI][PubMed]
  • 14. Starita LM, Parvin JD. The multiple nuclear functions of BRCA1: transcription, ubiquitination and DNA repair. Curr Opin Cell Biol. 2003; 15(3): 345-50[PubMed]
  • 15. Hilton JL, Geisler JP, Rathe JA, Hattermann-Zogg MA, DeYoung B, Buller RE. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst. 2002; 94(18): 1396-406[PubMed]
  • 16. Lodish H, Berk A, Zipursky L, Matsudaira P, Baltimore D. Molecular Cell Biology. 2000; : 551-5
  • 17. Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S, et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res. 2000; 60(19): 5329-33[PubMed]
  • 18. Markowitz S. DNA repair defects inactivate tumor suppressor genes and induce hereditary and sporadic colon cancers. J Clin Oncol. 2000; 18(21 Suppl): 75S-80S[PubMed]
  • 19. Mdas P, Singal R. DNA Methlation and cancer. Clinical Oncology J. 2004; 22(22): 632-42
  • 20. Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res. 2006; 8(4)[DOI][PubMed]
  • 21. Robertson KD. DNA methylation and human disease. Nat Rev Genet. 2005; 6(8): 597-610[DOI][PubMed]
  • 22. Chiang JW, Karlan BY, Cass L, Baldwin RL. BRCA1 promoter methylation predicts adverse ovarian cancer prognosis. Gynecol Oncol. 2006; 101(3): 403-10[DOI][PubMed]
  • 23. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003; 72(5): 1117-30[DOI][PubMed]
  • 24. Motoyama N, Naka K. DNA damage tumor suppressor genes and genomic instability. Curr Opin Genet Dev. 2004; 14(1): 11-6[DOI][PubMed]
  • 25. Paige AJ. Redefining tumour suppressor genes: exceptions to the two-hit hypothesis. Cell Mol Life Sci. 2003; 60(10): 2147-63[DOI][PubMed]
  • 26. Olek A, Oswald J, Walter J. A modified and improved method for bisulphite based cytosine methylation analysis. Nucleic Acids Res. 1996; 24(24): 5064-6[PubMed]
  • 27. An J, Wei Q, Liu Z, Lu KH, Cheng X, Mills GB, et al. Messenger RNA expression and methylation of candidate tumor-suppressor genes and risk of ovarian cancer-a case-control analysis. Int J Mol Epidemiol Genet. 2010; 1(1): 1-10[PubMed]
  • 28. Chobanian N, Dietrich C3. Ovarian cancer. Surg Clin North Am. 2008; 88(2): 285-99[DOI][PubMed]
  • 29. Welcsh PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet. 2001; 10(7): 705-13[PubMed]
  • 30. Dhillon VS, Shahid M, Husain SA. CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin. Mol Cancer. 2004; 3: 33[DOI][PubMed]
  • 31. Nurhan C, Serpil T, Engin O. Methylation status of CpG islands at sites −59 to +96 in exon 1 of the BRCA2 gene varies in mammary tissue among women with sporadic breast cancer. Genet J. 2008; 87(2): 155-8
  • 32. Collins N, Wooster R, Stratton MR. Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers. Br J Cancer. 1997; 76(9): 1150-6[PubMed]
  • 33. Bosviel R, Michard E, Lavediaux G, Kwiatkowski F, Bignon YJ, Bernard-Gallon DJ. Peripheral blood DNA methylation detected in the BRCA1 or BRCA2 promoter for sporadic ovarian cancer patients and controls. Clin Chim Acta. 2011; 412(15-16): 1472-5[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments